JPRN-UMIN000011363
Completed
Phase 2
Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer - Phase IIstudy of FOLFIRI+biweekly cetuximab
Dept of Surgical Oncology Osaka City University Graduate School of Medicine0 sites20 target enrollmentAugust 3, 2013
Conditionsunresectable colorectal cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- unresectable colorectal cancer
- Sponsor
- Dept of Surgical Oncology Osaka City University Graduate School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •severe dysfunction of bone marrow, liver, renal, and cardiac function no prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co\-existing malignancy or malignancy within the last five years prior to enrollment no severe concurrent medical or psychiatric illness no a known hypersensitivity to the study drugs none of the patients were pregnant or lactating.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.unresectable colorectal cancerJPRN-UMIN000011364Osaka City University20
Completed
Phase 2
Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancerColorectal cancerJPRN-UMIN000023026Department of Clinical Oncology, St. Marianna University School of Medicine54
Active, not recruiting
Phase 1
Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / VTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34
Completed
Phase 2
Phase II trial of bi-weekly cetuximab plus mFOLFOX6 or cetuximab plus mFOLFIRI for unresectable advanced or recurrent KRAS wild type colorectal cancer (T-CORE1201)colorectal cancerJPRN-UMIN000008298Tohoku Clinical Oncoogy, Research and Education Society(T-CORE)66
Completed
Phase 1
Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancerRAS wild-type unresectable colorectal cancerJPRN-UMIN000015620Aichi Cancer Center Hospital12